Credit Suisse, Autodesk And Other Big Losers From Wednesday
U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session.
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers
Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers
DBV Technologies (NASDAQ:DBVT) stock increased by 18.7% to $1.9 during Tuesday's after-market session. The company's market cap stands at $356.7 million.
GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day
GSK plc (NYSE:GSK) will transfer its NY-ESO cell therapy program and the right to the PRAME cell therapy program to Adaptimmune Therapeutics…
Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Lowers Price Target to $1.5
Wells Fargo analyst Nick Abbott maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Equal-Weight and lowers the price target from $7 to $1.5.
Important Biotech Catalysts For September 9, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to…
Adaptimmune Reported 44% Objective Response Rate With a Single Dose of ADP-A2M4CD8 in 25 Heavily Pre-treated Patients With Late-stage Ovarian, Urothelial, and Head & Neck Cancers
Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces positive data from its signal-finding Phase 1 SURPASS trial.